CE-VST 01 JC
Alternative Names: CE-VST-01-JC; JCPyV-specific T cell therapy - CellevolveLatest Information Update: 16 Jun 2023
At a glance
- Originator Cellevolve
- Class Gene therapies; Neuroprotectants; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Progressive multifocal leukoencephalopathy
Most Recent Events
- 22 Apr 2023 Pharmacodynamics data from a preclinical trial in Progressive multifocal leukoencephalopathy presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
- 08 Dec 2022 Phase-I/II clinical trials in Progressive multifocal leukoencephalopathy in USA (IV) prior to December 2022 (Cellevolve pipeline, December 2022)
- 25 Oct 2022 CE-VST 01 JC receives Orphan Drug status for Progressive multifocal leukoencephalopathy in USA